vs
Side-by-side financial comparison of Aardvark Therapeutics, Inc. (AARD) and AbbVie (ABBV). Click either name above to swap in a different company.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for inflammatory, metabolic, and orphan diseases. It advances G-protein coupled receptor-targeting pipeline candidates, serving patient populations primarily in North America and global markets via R&D partnerships.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
AARD vs ABBV — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $16.6B |
| Net Profit | $-17.6M | $1.8B |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 27.3% |
| Net Margin | — | 10.9% |
| Revenue YoY | — | 10.0% |
| Net Profit YoY | — | 8354.5% |
| EPS (diluted) | $-0.81 | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $16.6B | ||
| Q3 25 | $0 | $15.8B | ||
| Q2 25 | $0 | $15.4B | ||
| Q1 25 | $0 | $13.3B | ||
| Q4 24 | — | $15.1B | ||
| Q3 24 | — | $14.5B | ||
| Q2 24 | — | $14.5B | ||
| Q1 24 | — | $12.3B |
| Q4 25 | $-17.6M | $1.8B | ||
| Q3 25 | $-16.3M | $186.0M | ||
| Q2 25 | $-14.4M | $938.0M | ||
| Q1 25 | $-9.3M | $1.3B | ||
| Q4 24 | — | $-22.0M | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 66.4% | ||
| Q2 25 | — | 71.8% | ||
| Q1 25 | — | 70.0% | ||
| Q4 24 | — | 70.9% | ||
| Q3 24 | — | 70.9% | ||
| Q2 24 | — | 70.9% | ||
| Q1 24 | — | 66.7% |
| Q4 25 | — | 27.3% | ||
| Q3 25 | — | 12.1% | ||
| Q2 25 | — | 31.7% | ||
| Q1 25 | — | 28.0% | ||
| Q4 24 | — | -9.9% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | 22.7% |
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 9.5% | ||
| Q1 24 | — | 11.1% |
| Q4 25 | $-0.81 | $1.02 | ||
| Q3 25 | $-0.75 | $0.10 | ||
| Q2 25 | $-0.66 | $0.52 | ||
| Q1 25 | $-0.71 | $0.72 | ||
| Q4 24 | — | $-0.03 | ||
| Q3 24 | — | $0.88 | ||
| Q2 24 | — | $0.77 | ||
| Q1 24 | — | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $110.0M | $5.3B |
| Total DebtLower is stronger | — | $58.9B |
| Stockholders' EquityBook value | $106.6M | $-3.3B |
| Total Assets | $117.2M | $134.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $110.0M | $5.3B | ||
| Q3 25 | $126.3M | $5.7B | ||
| Q2 25 | $141.8M | $6.5B | ||
| Q1 25 | $151.3M | $5.2B | ||
| Q4 24 | — | $5.6B | ||
| Q3 24 | — | $7.3B | ||
| Q2 24 | — | $13.2B | ||
| Q1 24 | — | $18.1B |
| Q4 25 | — | $58.9B | ||
| Q3 25 | — | $63.0B | ||
| Q2 25 | — | $63.0B | ||
| Q1 25 | — | $64.5B | ||
| Q4 24 | — | $60.3B | ||
| Q3 24 | — | $58.5B | ||
| Q2 24 | — | $58.0B | ||
| Q1 24 | — | $63.8B |
| Q4 25 | $106.6M | $-3.3B | ||
| Q3 25 | $122.4M | $-2.6B | ||
| Q2 25 | $136.9M | $-183.0M | ||
| Q1 25 | $150.7M | $1.4B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $6.0B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $8.0B |
| Q4 25 | $117.2M | $134.0B | ||
| Q3 25 | $133.2M | $133.9B | ||
| Q2 25 | $147.5M | $137.2B | ||
| Q1 25 | $157.0M | $136.2B | ||
| Q4 24 | — | $135.2B | ||
| Q3 24 | — | $143.4B | ||
| Q2 24 | — | $141.9B | ||
| Q1 24 | — | $148.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 45.44× | ||
| Q4 24 | — | 18.15× | ||
| Q3 24 | — | 9.70× | ||
| Q2 24 | — | 8.56× | ||
| Q1 24 | — | 7.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.8M | $5.2B |
| Free Cash FlowOCF − Capex | — | $4.9B |
| FCF MarginFCF / Revenue | — | 29.4% |
| Capex IntensityCapex / Revenue | — | 2.0% |
| Cash ConversionOCF / Net Profit | — | 2.87× |
| TTM Free Cash FlowTrailing 4 quarters | — | $17.8B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.8M | $5.2B | ||
| Q3 25 | $-16.1M | $7.0B | ||
| Q2 25 | $-9.8M | $5.2B | ||
| Q1 25 | $-11.4M | $1.6B | ||
| Q4 24 | — | $7.0B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | — | $2.3B | ||
| Q1 24 | — | $4.0B |
| Q4 25 | — | $4.9B | ||
| Q3 25 | $-16.1M | $6.6B | ||
| Q2 25 | $-9.9M | $4.9B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $6.8B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $3.8B |
| Q4 25 | — | 29.4% | ||
| Q3 25 | — | 42.1% | ||
| Q2 25 | — | 31.7% | ||
| Q1 25 | — | 10.5% | ||
| Q4 24 | — | 44.7% | ||
| Q3 24 | — | 35.9% | ||
| Q2 24 | — | 14.0% | ||
| Q1 24 | — | 31.3% |
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | — | 2.87× | ||
| Q3 25 | — | 37.76× | ||
| Q2 25 | — | 5.49× | ||
| Q1 25 | — | 1.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.49× | ||
| Q2 24 | — | 1.66× | ||
| Q1 24 | — | 2.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
